DK1644397T3 - Specifik glucocorticosteroidforbindelse som har antiinflammatorisk aktivitet - Google Patents
Specifik glucocorticosteroidforbindelse som har antiinflammatorisk aktivitetInfo
- Publication number
- DK1644397T3 DK1644397T3 DK04741020.4T DK04741020T DK1644397T3 DK 1644397 T3 DK1644397 T3 DK 1644397T3 DK 04741020 T DK04741020 T DK 04741020T DK 1644397 T3 DK1644397 T3 DK 1644397T3
- Authority
- DK
- Denmark
- Prior art keywords
- inflammatory activity
- glucocorticosteroid compound
- specific
- specific glucocorticosteroid
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0316290.6A GB0316290D0 (en) | 2003-07-11 | 2003-07-11 | Novel compounds |
PCT/EP2004/007820 WO2005005452A1 (en) | 2003-07-11 | 2004-07-09 | Specific glucocorticosteroid compound having anti- inflammatory activity |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1644397T3 true DK1644397T3 (da) | 2010-08-23 |
Family
ID=27742019
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04763226.0T DK1644398T3 (da) | 2003-07-11 | 2004-07-09 | Specifik glucocorticosteroidforbindelse med antiinflammatorisk aktivitet |
DK04741020.4T DK1644397T3 (da) | 2003-07-11 | 2004-07-09 | Specifik glucocorticosteroidforbindelse som har antiinflammatorisk aktivitet |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04763226.0T DK1644398T3 (da) | 2003-07-11 | 2004-07-09 | Specifik glucocorticosteroidforbindelse med antiinflammatorisk aktivitet |
Country Status (31)
Country | Link |
---|---|
US (6) | US7291609B2 (da) |
EP (3) | EP1644397B1 (da) |
JP (3) | JP4709751B2 (da) |
KR (2) | KR101029207B1 (da) |
CN (3) | CN1849330B (da) |
AR (2) | AR045901A1 (da) |
AT (1) | ATE467638T1 (da) |
AU (2) | AU2004255855B2 (da) |
BR (2) | BRPI0412527A (da) |
CA (2) | CA2531905C (da) |
CY (2) | CY1110149T1 (da) |
DE (1) | DE602004027137D1 (da) |
DK (2) | DK1644398T3 (da) |
ES (3) | ES2400821T3 (da) |
GB (1) | GB0316290D0 (da) |
HK (2) | HK1089185A1 (da) |
HR (2) | HRP20100359T1 (da) |
IL (3) | IL172777A (da) |
IS (3) | IS2776B (da) |
MA (2) | MA27897A1 (da) |
MX (2) | MXPA06000442A (da) |
MY (2) | MY140987A (da) |
NO (2) | NO332041B1 (da) |
NZ (2) | NZ544577A (da) |
PL (2) | PL1644397T3 (da) |
PT (2) | PT1644397E (da) |
RU (3) | RU2359973C2 (da) |
SI (2) | SI1644397T1 (da) |
TW (2) | TWI367888B (da) |
WO (2) | WO2005005451A1 (da) |
ZA (2) | ZA200600223B (da) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0125259D0 (en) * | 2001-10-20 | 2001-12-12 | Glaxo Group Ltd | Novel compounds |
GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
DE102004025966A1 (de) * | 2004-05-21 | 2005-12-15 | Schering Ag | Estradiol-Prodrugs |
DE102004025985A1 (de) * | 2004-05-21 | 2005-12-15 | Schering Ag | Estriol- und Estetrol-Prodrugs |
US20090124588A1 (en) * | 2005-01-10 | 2009-05-14 | Glaxo Group Limited | Androstane 17-Alpha-Carbonate for Use in the Treatment of Inflammatory and Allergic Conditions |
EP1841780B1 (en) * | 2005-01-10 | 2011-07-27 | Glaxo Group Limited | Androstane 17-alpha-carbonate derivatives for use in the treatment of allergic and inflammatory conditions |
CA2603433A1 (en) * | 2005-03-30 | 2006-10-05 | Schering Corporation | Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist |
WO2007011743A2 (en) | 2005-07-14 | 2007-01-25 | Lipothera, Inc. | Sustained release enhanced lipolytic formulation for regional adipose tissue treatment |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
US7943651B2 (en) | 2006-04-20 | 2011-05-17 | Glaxo Group Limited | Compounds |
GB0611587D0 (en) | 2006-06-12 | 2006-07-19 | Glaxo Group Ltd | Novel compounds |
GB0615108D0 (en) * | 2006-07-28 | 2006-09-06 | Glaxo Group Ltd | Novel formulations |
PL2077830T3 (pl) * | 2006-10-17 | 2013-04-30 | Lithera Inc | Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej |
AR065804A1 (es) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento |
MX2010012814A (es) | 2008-05-23 | 2010-12-20 | Amira Pharmaceuticals Inc | Inhibidor de proteina activadora de 5-lipoxigenasa. |
ES2566339T3 (es) | 2008-06-05 | 2016-04-12 | Glaxo Group Limited | Derivados de 4-carboxamida indazol útiles como inhibidores de PI3-quinasas |
US20100160351A1 (en) * | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
WO2010071865A1 (en) | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
WO2010102958A1 (en) | 2009-03-09 | 2010-09-16 | Glaxo Group Limited | 4-oxadiazol-2 -yl- indazoles as inhibitors of p13 kinases |
EP2406249A1 (en) | 2009-03-10 | 2012-01-18 | Glaxo Group Limited | Indole derivatives as ikk2 inhibitors |
WO2010106016A1 (en) | 2009-03-17 | 2010-09-23 | Glaxo Group Limited | Pyrimidine derivatives used as itk inhibitors |
EP2408458A1 (en) | 2009-03-19 | 2012-01-25 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
EP2408916A2 (en) | 2009-03-19 | 2012-01-25 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
MX2011009724A (es) | 2009-03-19 | 2011-10-14 | Merck Sharp & Dohme | Inhibicion mediada por interferencia de acido ribonucleico de la expresion del gen del factor de transcripcion basico de cierre de leucina 1 de homologia de btb y cnc 1, usando el listado de secuencias de acido nucleico corto de interferencia. |
EP2408915A2 (en) | 2009-03-19 | 2012-01-25 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010111471A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20120004281A1 (en) | 2009-03-27 | 2012-01-05 | Merck Sharp & Dohme Corp | RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
WO2010111464A1 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
EP2411520A2 (en) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
JP2012521765A (ja) | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸(siNA)を用いた細胞内接着分子1(ICAM−1)遺伝子発現のRNA干渉媒介性阻害 |
US20100273744A1 (en) | 2009-04-24 | 2010-10-28 | Paul Martin Gore | Compounds |
WO2010122088A1 (en) | 2009-04-24 | 2010-10-28 | Glaxo Group Limited | Pyrazole and triazole carboxamides as crac channel inhibitors |
BRPI1016219B8 (pt) | 2009-04-30 | 2021-05-25 | Glaxo Group Ltd | composto indazol substituído com oxazol, e, composição farmacêutica |
US9132084B2 (en) * | 2009-05-27 | 2015-09-15 | Neothetics, Inc. | Methods for administration and formulations for the treatment of regional adipose tissue |
CA2760284A1 (en) | 2009-05-29 | 2010-12-02 | Pfizer Limited | Novel glucocorticoid receptor agonists |
WO2011032175A1 (en) | 2009-09-14 | 2011-03-17 | Nuon Therapeutics, Inc. | Combination formulations of tranilast and allopurinol and methods related thereto |
WO2011067366A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Indazole derivatives as pi 3 - kinase inhibitors |
JP2013512879A (ja) | 2009-12-03 | 2013-04-18 | グラクソ グループ リミテッド | Pi3キナーゼの阻害剤としてのベンズピラゾール誘導体 |
WO2011067364A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Novel compounds |
JP2013517294A (ja) * | 2010-01-15 | 2013-05-16 | リセラ,インク. | 凍結乾燥ケーキ製剤 |
WO2011110575A1 (en) | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases |
GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
PL2614058T3 (pl) | 2010-09-08 | 2015-12-31 | Glaxosmithkline Ip Dev Ltd | Polimorfy i sole n-[5-[4-(5-{[(2r,6s)-2,6-dimetylo-4-morfolinylo]-metylo}-1,3-oksazol-2-ilo)-1h-indazol-6-ilo]-2-(metyloksy)-3-pirydynylo]metanosulfonamidu |
ES2602972T3 (es) | 2010-09-08 | 2017-02-23 | Glaxosmithkline Intellectual Property Development Limited | Derivados de indazol para su uso en el tratamiento de infección por virus de la gripe |
US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
WO2012035055A1 (en) | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Novel compounds |
ES2532213T3 (es) | 2010-10-21 | 2015-03-25 | Glaxo Group Limited | Compuestos de pirazol que actúan contra afecciones alérgicas, inmunitarias e inflamatorias |
WO2012052459A1 (en) | 2010-10-21 | 2012-04-26 | Glaxo Group Limited | Pyrazole compounds acting against allergic, inflammatory and immune disorders |
GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
US9597531B2 (en) | 2010-11-24 | 2017-03-21 | Neothetics, Inc. | Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging |
WO2012116217A1 (en) | 2011-02-25 | 2012-08-30 | Irm Llc | Compounds and compositions as trk inhibitors |
EP2683716A1 (en) | 2011-03-11 | 2014-01-15 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
GB201104153D0 (en) | 2011-03-11 | 2011-04-27 | Glaxo Group Ltd | Novel compounds |
EP3007697B1 (en) | 2013-06-14 | 2020-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Rac1 inhibitors for inducing bronchodilation |
KR20160062178A (ko) | 2013-10-17 | 2016-06-01 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 호흡기 질병의 치료를 위한 pi3k 억제제 |
WO2015055690A1 (en) | 2013-10-17 | 2015-04-23 | Glaxosmithkline Intellectual Property Development Limited | Pi3k inhibitor for treatment of respiratory disease |
WO2015173701A2 (en) | 2014-05-12 | 2015-11-19 | Glaxosmithkline Intellectual Property (No. 2) Limited | Pharmaceutical compositions for treating infectious diseases |
GB201602527D0 (en) | 2016-02-12 | 2016-03-30 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
JP2019524792A (ja) | 2016-08-08 | 2019-09-05 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 化合物 |
GB201706102D0 (en) | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
GB201712081D0 (en) | 2017-07-27 | 2017-09-13 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
US11759472B2 (en) | 2017-11-21 | 2023-09-19 | Cs Pharmaceuticals Limited | Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface |
WO2019104207A2 (en) * | 2017-11-21 | 2019-05-31 | Axerovision, Inc. | Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface |
EP4125919A1 (en) | 2020-03-26 | 2023-02-08 | GlaxoSmithKline Intellectual Property Development Limited | Cathepsin inhibitors for preventing or treating viral infections |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3943124A (en) * | 1970-12-17 | 1976-03-09 | Gordon Hanley Phillipps | Chemical compounds |
GB1384372A (en) | 1971-01-20 | 1975-02-19 | Glaxo Lab Ltd | Dereivatives of 17alpha-hydroxyandrost-4-ene-17beta-carboxylic acids |
US3686978A (en) | 1971-04-09 | 1972-08-29 | Fairfied Mfg Co Inc | Plantetary reduction wheel hub |
GB1438940A (en) | 1972-07-19 | 1976-06-09 | Glaxo Lab Ltd | 17beta-haloalkoxycarbonyl-17alpha-oxysteroids |
US4093721A (en) * | 1974-08-30 | 1978-06-06 | Glaxo Laboratories Limited | Pharmaceutical compositions of 6α,9α-difluoro-androst-4-ene-17β-carboxylates and derivatives thereof |
GB1514476A (en) | 1974-08-30 | 1978-06-14 | Glaxo Lab Ltd | Alkyl and haloalkyl androst-4-ene and androsta-1,4-diene-17beta-carboxylates |
GB2137206B (en) | 1980-02-15 | 1985-04-03 | Glaxo Group Ltd | Androstane 17-carbothioc acid derivatives |
SE449106B (sv) * | 1980-07-10 | 1987-04-06 | Otsuka Pharma Co Ltd | Steroid med anti-inflammatorisk verkan samt komposition innehallande denna |
US4996335A (en) * | 1980-07-10 | 1991-02-26 | Nicholas S. Bodor | Soft steroids having anti-inflammatory activity |
DE3786174T2 (de) * | 1987-10-13 | 1993-10-21 | Nicholas S Bodor | Weiche steroide mit anti-entzündungswirkung. |
US5990099A (en) | 1988-10-31 | 1999-11-23 | Alcon Laboratories, Inc. | Angiostatic agents and methods and compositions for controlling ocular hypertension |
GB9127376D0 (en) | 1991-12-24 | 1992-02-19 | Wellcome Found | Amidino derivatives |
CZ283425B6 (cs) | 1992-04-02 | 1998-04-15 | Smithkline Beecham Corporation | Fenylové deriváty a farmaceutické prostředky s jejich obsahem |
ATE191470T1 (de) | 1994-06-15 | 2000-04-15 | Wellcome Found | Enzymhemmer |
US6172054B1 (en) | 1995-06-15 | 2001-01-09 | Alcon Laboratories, Inc. | Combination therapy for lowering and controlling intraocular pressure |
AU1970197A (en) | 1996-05-09 | 1997-11-26 | Alcon Laboratories, Inc. | Use of steroid compounds to prevent non-cancerous tissue growth |
MY117948A (en) | 1997-01-13 | 2004-08-30 | Glaxo Group Ltd | Nitride oxide synthase inhibitors. |
US6245804B1 (en) | 1997-05-30 | 2001-06-12 | Schering Aktiengesellschaft | Nonsteroidal gestagens |
DE19723722A1 (de) | 1997-05-30 | 1998-12-10 | Schering Ag | Nichtsteroidale Gestagene |
WO1999016768A1 (en) | 1997-10-01 | 1999-04-08 | Kyowa Hakko Kogyo Co., Ltd. | Benzofuran derivatives |
AU9281298A (en) | 1997-10-01 | 1999-04-23 | Kyowa Hakko Kogyo Co. Ltd. | Benzodioxole derivatives |
US6506766B1 (en) | 1998-02-13 | 2003-01-14 | Abbott Laboratories | Glucocortiocoid-selective antinflammatory agents |
EP1070056B1 (en) | 1998-03-14 | 2004-06-30 | ALTANA Pharma AG | Phthalazinone pde iii/iv inhibitors |
GB9811599D0 (en) | 1998-05-30 | 1998-07-29 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
CA2371273A1 (en) | 1999-05-04 | 2000-11-09 | Andrew Fensome | Tetracyclic progesterone receptor modulator compounds and methods |
ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
US6263209B1 (en) | 1999-07-28 | 2001-07-17 | Motorola, Inc. | Method and apparatus in a wireless communication system for creating a learning function |
CO5180649A1 (es) | 1999-09-01 | 2002-07-30 | Abbott Lab | Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes |
OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
GB0015876D0 (en) | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
AU2001275760B2 (en) * | 2000-08-05 | 2005-03-17 | Glaxo Group Limited | 6.alpha., 9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl) oxy!-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid S-fluoromethyl ester as an anti-inflammatory agent |
US7101882B2 (en) | 2000-09-29 | 2006-09-05 | Glaxo Group Limited | Morpholin-acetamide derivatives for the treatment of inflammatory diseases |
CA2428799A1 (en) | 2000-11-16 | 2002-05-23 | Alcon Manufacturing, Ltd. | Combination therapy for lowering and controlling intraocular pressure |
GB0031179D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
US6484903B2 (en) | 2001-01-09 | 2002-11-26 | Riverwood International Corporation | Carton with an improved dispensing feature in combination with a unique handle |
GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
EP1366025B1 (en) | 2001-03-08 | 2007-06-27 | Glaxo Group Limited | Agonists of beta-adrenoreceptors |
ATE381537T1 (de) | 2001-03-22 | 2008-01-15 | Glaxo Group Ltd | Formanilid-derivative als beta2-adrenorezeptor- agonisten |
HUP0400070A2 (hu) * | 2001-04-30 | 2004-04-28 | Glaxo Group Limited | 17alfa-helyzetben ciklusos észtercsoportot tartalmazó androsztán-17béta-karbotiosav-észter-származékok mint gyulladásgátló szerek, eljárás a vegyületek előállítására és ezeket tartalmazó gyógyszerkészítmények |
ATE417606T1 (de) | 2001-09-14 | 2009-01-15 | Glaxo Group Ltd | Phenethanolamin-derivate zur behandlung von erkrankungen der atemwege |
GB0125259D0 (en) * | 2001-10-20 | 2001-12-12 | Glaxo Group Ltd | Novel compounds |
WO2003042160A1 (en) | 2001-11-13 | 2003-05-22 | Theravance, Inc. | Aryl aniline beta-2 adrenergic receptor agonists |
ATE346058T1 (de) | 2002-01-14 | 2006-12-15 | Boehringer Ingelheim Pharma | Glucocorticoid mimetika, verfahren zu ihrer herstellung, pharmazeutische formulierungen sie enthaltend und verwendungen davon |
WO2003072592A1 (en) * | 2002-01-15 | 2003-09-04 | Glaxo Group Limited | 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents |
JP4745609B2 (ja) | 2002-01-22 | 2011-08-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | グルココルチコイドレセプターのための非ステロイド性リガンド、その組成物および使用 |
GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
EA008830B1 (ru) | 2002-03-26 | 2007-08-31 | Бёрингер Ингельхайм Фармасьютиклз, Инк. | Миметики глюкокортикоидов, способы их получения, фармацевтические композиции и их применение |
EP1490317A1 (en) | 2002-03-26 | 2004-12-29 | Boehringer Ingelheim Pharmaceuticals Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
DE10215316C1 (de) | 2002-04-02 | 2003-12-18 | Schering Ag | Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer |
US6897224B2 (en) | 2002-04-02 | 2005-05-24 | Schering Ag | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors |
US7282591B2 (en) | 2002-04-11 | 2007-10-16 | Merck & Co., Inc. | 1h-benzo{f}indazol-5-yl derivatives as selective glucocorticoid receptor modulators |
JP2005523920A (ja) | 2002-04-25 | 2005-08-11 | グラクソ グループ リミテッド | フェネタノールアミン誘導体 |
US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
ES2518940T3 (es) | 2002-07-08 | 2014-11-06 | Pfizer Products Inc. | Moduladores del receptor de glucocorticoides |
US6995181B2 (en) | 2002-07-18 | 2006-02-07 | Bristol-Myers Squibb Co. | Modulators of the glucocorticoid receptor and method |
AU2003251969A1 (en) | 2002-07-18 | 2004-02-09 | Bristol-Myers Squibb Company | Compositions and methods involving nuclear hormone receptor site ii |
GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
CA2496175A1 (en) | 2002-08-21 | 2004-03-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
CN100387598C (zh) | 2002-09-16 | 2008-05-14 | 葛兰素集团有限公司 | 吡唑并[3,4-b]吡啶化合物及其作为磷酸二酯酶抑制剂的用途 |
GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
JP4520309B2 (ja) | 2002-09-20 | 2010-08-04 | メルク・シャープ・エンド・ドーム・コーポレイション | 選択的糖質コルチコイド受容体調節剤としてのオクタヒドロ−2−H−ナフト[1,2−f]インドール−4−カルボキサミド誘導体 |
AU2003298094A1 (en) | 2002-10-22 | 2004-05-13 | Glaxo Group Limited | Medicinal arylethanolamine compounds |
AR041724A1 (es) | 2002-10-28 | 2005-05-26 | Glaxo Group Ltd | Compuestos derivados de fenetanolamina y su utilizacion en composiciones farmaceuticas |
GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
-
2003
- 2003-07-11 GB GBGB0316290.6A patent/GB0316290D0/en not_active Ceased
-
2004
- 2004-07-08 AR ARP040102428A patent/AR045901A1/es unknown
- 2004-07-08 AR ARP040102427A patent/AR045900A1/es unknown
- 2004-07-09 CN CN2004800256690A patent/CN1849330B/zh not_active Expired - Fee Related
- 2004-07-09 AU AU2004255855A patent/AU2004255855B2/en not_active Ceased
- 2004-07-09 KR KR1020067000690A patent/KR101029207B1/ko active IP Right Grant
- 2004-07-09 PT PT04741020T patent/PT1644397E/pt unknown
- 2004-07-09 AU AU2004255854A patent/AU2004255854B2/en not_active Ceased
- 2004-07-09 PT PT47632260T patent/PT1644398E/pt unknown
- 2004-07-09 CN CN2011102290522A patent/CN102372756A/zh active Pending
- 2004-07-09 ES ES04763226T patent/ES2400821T3/es active Active
- 2004-07-09 US US10/564,299 patent/US7291609B2/en active Active
- 2004-07-09 MX MXPA06000442A patent/MXPA06000442A/es active IP Right Grant
- 2004-07-09 DK DK04763226.0T patent/DK1644398T3/da active
- 2004-07-09 WO PCT/EP2004/007819 patent/WO2005005451A1/en active Application Filing
- 2004-07-09 US US10/564,325 patent/US7288536B2/en active Active
- 2004-07-09 CA CA2531905A patent/CA2531905C/en not_active Expired - Fee Related
- 2004-07-09 TW TW093120698A patent/TWI367888B/zh not_active IP Right Cessation
- 2004-07-09 CN CN2004800255908A patent/CN1845933B/zh not_active Expired - Fee Related
- 2004-07-09 RU RU2005141226/04A patent/RU2359973C2/ru active
- 2004-07-09 KR KR1020067000738A patent/KR101075324B1/ko active IP Right Grant
- 2004-07-09 NZ NZ544577A patent/NZ544577A/en unknown
- 2004-07-09 DK DK04741020.4T patent/DK1644397T3/da active
- 2004-07-09 RU RU2005141064/04A patent/RU2348645C2/ru active
- 2004-07-09 PL PL04741020T patent/PL1644397T3/pl unknown
- 2004-07-09 BR BRPI0412527-4A patent/BRPI0412527A/pt not_active Application Discontinuation
- 2004-07-09 WO PCT/EP2004/007820 patent/WO2005005452A1/en active Application Filing
- 2004-07-09 PL PL04763226T patent/PL1644398T3/pl unknown
- 2004-07-09 DE DE602004027137T patent/DE602004027137D1/de active Active
- 2004-07-09 EP EP04741020A patent/EP1644397B1/en active Active
- 2004-07-09 SI SI200431471T patent/SI1644397T1/sl unknown
- 2004-07-09 AT AT04741020T patent/ATE467638T1/de active
- 2004-07-09 MY MYPI20042746A patent/MY140987A/en unknown
- 2004-07-09 JP JP2006518180A patent/JP4709751B2/ja not_active Expired - Fee Related
- 2004-07-09 MY MYPI20042752A patent/MY137944A/en unknown
- 2004-07-09 EP EP11151276.0A patent/EP2380898B1/en active Active
- 2004-07-09 BR BRPI0412526-6A patent/BRPI0412526A/pt not_active Application Discontinuation
- 2004-07-09 SI SI200432006T patent/SI1644398T1/sl unknown
- 2004-07-09 EP EP04763226A patent/EP1644398B1/en active Active
- 2004-07-09 CA CA2531911A patent/CA2531911C/en not_active Expired - Fee Related
- 2004-07-09 TW TW093120707A patent/TWI338694B/zh not_active IP Right Cessation
- 2004-07-09 JP JP2006518181A patent/JP4709752B2/ja not_active Expired - Fee Related
- 2004-07-09 NZ NZ544576A patent/NZ544576A/en unknown
- 2004-07-09 ES ES11151276T patent/ES2433665T3/es active Active
- 2004-07-09 MX MXPA06000443A patent/MXPA06000443A/es active IP Right Grant
- 2004-07-09 ES ES04741020T patent/ES2343685T3/es active Active
-
2005
- 2005-12-22 IS IS8194A patent/IS2776B/is unknown
- 2005-12-22 IL IL172777A patent/IL172777A/en active IP Right Grant
- 2005-12-22 IL IL172776A patent/IL172776A/en active IP Right Grant
- 2005-12-22 IS IS8193A patent/IS2909B/is unknown
-
2006
- 2006-01-06 MA MA28701A patent/MA27897A1/fr unknown
- 2006-01-06 NO NO20060110A patent/NO332041B1/no not_active IP Right Cessation
- 2006-01-06 MA MA28703A patent/MA27899A1/fr unknown
- 2006-01-06 NO NO20060111A patent/NO333263B1/no not_active IP Right Cessation
- 2006-01-10 ZA ZA200600223A patent/ZA200600223B/en unknown
- 2006-01-10 ZA ZA200600226A patent/ZA200600226B/en unknown
- 2006-08-29 HK HK06109621.2A patent/HK1089185A1/xx not_active IP Right Cessation
- 2006-08-29 HK HK06109622.1A patent/HK1089186A1/xx not_active IP Right Cessation
-
2007
- 2007-09-28 US US11/863,439 patent/US7524970B2/en active Active
- 2007-09-28 US US11/863,390 patent/US7638508B2/en active Active
- 2007-09-28 US US11/863,419 patent/US20080021231A1/en not_active Abandoned
-
2009
- 2009-04-03 RU RU2009112207/04A patent/RU2009112207A/ru not_active Application Discontinuation
-
2010
- 2010-03-01 US US12/714,961 patent/US20100152148A1/en not_active Abandoned
- 2010-06-29 HR HR20100359T patent/HRP20100359T1/hr unknown
- 2010-06-30 CY CY20101100601T patent/CY1110149T1/el unknown
- 2010-12-23 IL IL210209A patent/IL210209A0/en unknown
-
2011
- 2011-01-07 JP JP2011001699A patent/JP2011093929A/ja active Pending
-
2013
- 2013-01-23 HR HRP20130056TT patent/HRP20130056T1/hr unknown
- 2013-03-19 CY CY20131100230T patent/CY1113836T1/el unknown
-
2014
- 2014-10-28 IS IS050094A patent/IS2928B/is unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1644397T3 (da) | Specifik glucocorticosteroidforbindelse som har antiinflammatorisk aktivitet | |
CY2014016I1 (el) | Νεες ενωσεις που εχουν ανασταλτικη δραστικοτητα εναντια στον εξαρτωμενο απο το νατριο μεταφορεα | |
IS8941A (is) | Efnasambönd með bólgueyðandi virkni | |
NO20052884D0 (no) | Substituerte indolpyridinforbindelser som anti-infeksjonsmidler. | |
NO20051688D0 (no) | Farmasoytiske blandinger som har en modifisert baerer | |
IS7879A (is) | Ný efnasambönd | |
IS8228A (is) | Ný asetídínefnasambönd | |
IS8269A (is) | Setin fúrókrómen efnasambönd með bólgueyðandi virkni | |
DE602005008307D1 (de) | Kassettenanordnung | |
DK1556377T3 (da) | Cyclopropylthienylcarboxamider som fungicider | |
ITMI20050680A1 (it) | Nuovi composti anti-infiammatori | |
NO20050127L (no) | 9-alfa-substituerte ostratriener som selektivt aktive ostrogener | |
DK1691814T3 (da) | Antiinflammatoriske midler | |
ATE408989T1 (de) | Beschichtete zubereitungen, enthaltend mindestens ein hydroformiat | |
ES1059263Y (es) | Cepillo integral multiple | |
ES1053690Y (es) | Estructura para construccion de viviendas. | |
DK1381609T3 (da) | 5-Halogen-6-phenyl-7-fluoralkylamino-triazolopyrimidiner som fungicider | |
DE50208112D1 (de) | Nachgiebige Seilabspannung für Wasserbauwerke | |
NO20035659D0 (no) | Forbindelsesklynger | |
ES1053673Y (es) | Pieza para construccion. | |
ES1055569Y (es) | Soporte de fijacion para nudos de estructuras. | |
ES1056395Y (es) | Disposicion para la construccion de edificaciones perfeccionada. | |
ES1056362Y (es) | Rasillon para construccion. | |
SE0202908D0 (sv) | New compounds | |
SE0203751D0 (sv) | New Compounds |